Different doses of ADVATE for immune tolerance in boys with hemophilia A and inhibitors
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial tests how different doses and schedules of the factor VIII medicine ADVATE can train the immune system to accept factor VIII again in boys with hemophilia A who have developed inhibitors. The goal is to find a better way to help their bodies stop blocking the treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have severe hemophilia A (factor VIII level less than 2%)
- You have tested positive for factor VIII inhibitors
- You have never had an allergic reaction to factor VIII concentrates, like ADVATE
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a therapy called ITI (using SCT800 alone or with daratumumab) to help people with hemophilia A who have inhibitor antibodies that reduce bleeding treatments from working. It may be an option if you’re an adolescent or adult with a high inhibitor level and have not already failed this kind of immune “ITI” treatment before.
This study tests a treatment called Altuviiio for children with severe hemophilia A who have developed inhibitors (antibodies that block factor replacement). The goal is to help the body become tolerant to factor therapy again, preventing bleeding episodes.
This trial tests whether adjusting emicizumab (Hemlibra) doses based on your body's drug levels can safely maintain good bleed control in people with hemophilia A who have been on the drug for at least a year.
This study tests a new medicine called SCT800 for boys with severe hemophilia A who have never been treated with factor VIII before. The goal is to see if it works safely to prevent bleeding.
This trial tests a new longer-lasting factor VIII medicine (FRSW107) for on-demand treatment of bleeding episodes. It is for males with severe hemophilia A who have been previously treated at least 150 times.
This study tests an experimental oral medication (Inno8) for people with hemophilia A. It aims to find the best dose and see how the body handles it. You may be able to join if you have mild to severe hemophilia A and are not on other preventive treatments.
Hear when a new Hemophilia A With Inhibitor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.